Will Prolyl Hydroxylase Inhibitors Supplant Erythropoiesis-Stimulating Agents and IV Iron in the Treatment of Chemotherapy-Induced Anemia?

Mené sur 159 patients atteints d'un cancer (tumeur non myéloïde), cet essai de phase III évalue l'efficacité et la sécurité du roxadustat pour prendre en charge une anémie induite par la chimiothérapie

Résumé en anglais

Treatment of anemia is a major supportive care issue for many patients with cancer. It can lead to treatment delays and adversely affect quality of life. Current anemia treatment options include packed red blood cell (pRBC) transfusion, intravenous iron, and erythropoiesis-stimulating agents (ESAs).1,2 There are significant risks associated with use of pRBCs and ESAs to treat cancer-related anemia. Transfusion risks include transfusion reactions, potential pathogen transmission, volume overload, and an increased risk of thrombosis and mortality.2 ESAs have boxed warnings about possible increased risk of thrombosis, cancer progression, and death.2 Intravenous iron appears to have a lower risk of serious adverse events, but many hematology-oncology physicians still do not routinely use intravenous iron to treat cancer-associated anemia.